Upfront Diagnostics Secures $4.3M to Revolutionize Stroke Diagnosis with LVOne: A New Chapter in Life-Saving Care

Upfront Diagnostics is thrilled to announce that we have successfully raised £4,300,000, a significant milestone that will catalyze our mission to revolutionize medical diagnostics.

Founded in November 2017 in Cambridge, United Kingdom, our team of innovative students and entrepreneurs has been relentlessly focused on discovering groundbreaking biomarkers to enhance diagnostic accuracy and speed.

This latest round of funding will accelerate the development and broader deployment of our pioneering blood test, LVOne, the world’s first test specifically designed for rapid large vessel occlusion stroke diagnosis.

LVOne not only provides faster and more accurate results but also empowers clinicians, paramedics, and nurses with a critical tool to make life-saving decisions under pressure.

As healthcare systems globally face the immense challenges of time-critical conditions like stroke, our commitment is clear: to deliver diagnostic solutions that are both effective and cost-efficient.

The investment will be strategically channelled towards further research and development, scaling our manufacturing processes, and enhancing clinical trials to ensure that LVOne reaches every corner where it can make an impact.

With these funds, Upfront Diagnostics aims to pave the way towards a future where improved diagnostics can reduce hospital turnaround times and significantly boost patient outcomes.

We believe that by merging scientific excellence with a deep understanding of clinical needs, we can create products that not only save time but, more importantly, save lives.

Join us in our journey of innovation and commitment, because in medicine, every second counts.